Real World Population Pharmacokinetic Study in Childr Inflammatory Bowel Disease Discovers Novel Blood and Vedolizumab Clearance

Alimentary Pharmacology and Therapeutics

57, 524-539

DOI: 10.1111/apt.17277

Citation Report

#	Article	IF	Citations
1	Editorial: Achievements and Unresolved Questions in Improving the Pharmacokinetics of Vedolizumab in Adolescents With Inflammatory Bowel Disease. Alimentary Pharmacology and Therapeutics, 2023, 57, 565-566.	7.7	1
2	Editorial: Achievements and Unresolved Questions in Improving the Pharmacokinetics of Vedolizumab in Adolescents With Inflammatory Bowel Disease—Authors' Reply. Alimentary Pharmacology and Therapeutics, 2023, 57, 567-568.	7.7	0
3	Current Role of Monoclonal Antibody Therapy in Pediatric IBD: A Special Focus on Therapeutic Drug Monitoring and Treat-to-Target Strategies. Children, 2023, 10, 634.	3.0	7
4	The Role of Therapeutic Drug Monitoring in Children. Gastroenterology Clinics of North America, 2023, 52, 549-563.	3.6	6
5	Drug Clearance in Patients With Inflammatory Bowel Disease Treated With Biologics. Journal of Clinical Medicine, 2023, 12, 7132.	3.8	49
6	Gut Microbiome-Associated Predictors as Biomarkers of Response to Advanced Therapies in Inflammatory Bowel Disease: A Systematic Review. Gut Microbes, 2023, 15, 2287073.	15.6	53
7	De Novo Crohn's Disease Diagnosed in the Setting of Acute SARSCov- 2 Infection Requiring Escalation of Infliximab Therapy Guided by Personalized Pharmacokinetics. Journal of Pediatrics Perinatology and Child Health, 2024, 8, 1-4.	0.3	0
8	Gut Microbiota and Metabolites as Predictors of Biologics Response in Inflammatory Bowel Disease: A Comprehensive Systematic Review. Microbiological Research, 2024, 282, 127660.	9.9	52
9	Challenges in IBD Research 2024: Pragmatic Clinical Research. Inflammatory Bowel Diseases, 2024, 30, S55-S66.	5.5	7
10	Considerations in Paediatric and Adolescent Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2024, 18, ii31-ii45.	8.8	49
11	Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights From Real-World Pharmacokinetics. Pharmaceutics, 2024, 16, 1629.	7.5	5
12	Long-Term VEDOKIDS Results: Implications for Practice and Research. The Lancet Gastroenterology and Hepatology, 2025, 10, 189-190.	29.4	0
13	Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study. Alimentary Pharmacology and Therapeutics, 2025, 61, 1000-1010.	7.7	10
14	Editorial: Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab. Alimentary Pharmacology and Therapeutics, 2025, 61, 1063-1064.	7.7	0
15	Positionspapier der Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE) zum zulassungsüberschreitenden Gebrauch von für Erwachsene mit CED zugelassenen Biologika und Signalinhibitoren bei Kindern und Jugendlichen. Zeitschrift Fur Gastroenterologie, 2025, 63, 255-268.	0.6	2
16	Gut Microbiota in Different Treatment Response Types of Crohn's Disease Patients Treated With Biologics Over a Long Disease Course. Biomedicines, 2025, 13, 708.	4.9	5
17	Role of Gut Microbiota and Metabolomics in Predicting Response to Vedolizumab in Inflammatory Bowel Disease: A Systematic Review. Pharmaceutics, 2025, 17, 476.	7.5	5
18	Association of Serum Levels of Ustekinumab, Vedolizumab, and Faecal Calprotectin in Paediatric Patients With Inflammatory Bowel Diseases: A Prospective Observational Study. Paediatric Drugs, 2025, 27, 629-640.	4.6	1

#	Article	IF	Citations
19	North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2025, 81, 1100-1117.	3.3	22
20	The Right Drug at the Right Time: Key to IBD Success. Trends in Molecular Medicine, 2026, 32, 658-677.	15.6	2
21	Gut Microbiota as a Potential Predictor of Therapeutic Response in Adults With Crohn's Disease: A Systematic Review. World Journal of Gastrointestinal Pathophysiology, 2025, 16, 112961.	3.1	3
22	The Coming of Age of Model-Informed Precision Therapeutics for Children. Journal of Pediatric Pharmacology and Therapeutics, 2025, 30, 719-730.	1.6	1
23	Reshaping Study Design for Faster Extrapolation-Based Drug Approval in Pediatric Inflammatory Bowel Diseases: An ESPGHAN–NASPGHAN Position Paper. Journal of Pediatric Gastroenterology and Nutrition, 2026, 82, 867-894.	3.3	8
24	Off-Label Ustekinumab and Vedolizumab in Pediatric Anti-TNFα Refractory IBD: Therapeutic Drug Monitoring Insights From a Case Series. Pharmaceuticals, 2026, 19, 154.	6.1	0
25	Emerging Role of Gut Microbiota in Modulating Response to Therapies in IBD. Microorganisms, 2026, 14, 1082.	5.1	3
26	Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients With Inflammatory Bowel Disease. Clinical Pharmacokinetics, 2026, 65, 1377-1388.	4.0	0